



# Consolidated Financial Results for the 2<sup>nd</sup> Quarter of Fiscal 2021 and Full-Year Forecasts


# Disclaimer

---

- This material contains forward-looking statements that reflect management's current views, plans, and expectations based on information available at the time of preparation. These forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, future business decisions, and other internal and external factors that may cause the Company's actual results, performance, achievements, or financial position to be materially different from any future results expressed or implied by these forward-looking statements.
- Additionally, this information is subject to change without notice. Accordingly, other information should be used in addition to this material when making investment decisions.
- Olympus Corporation assumes no responsibility for any damage resulting from the use of this material.

# Changes in Reporting Structure

With the divestiture of the Imaging Business, it is disclosed as a discontinued operation from 2Q (based on IFRS)



- ✓ Profit (loss) from discontinued operation is disclosed in Consolidated Financial Results
- ✓ Performance of discontinued operation is disclosed as supplementary information

\* On September 30, 2020, Olympus divested its Imaging Business to a newly established wholly owned subsidiary of the Company (the "New Imaging Company"), through an absorption-type split. In addition, the Company concluded a final agreement with Japan Industrial Partners, Inc. on September 30, 2020 concerning the transfer of 95% of the shares of the New Imaging Company to OJ Holdings, Ltd., a special purpose company established by JIP. Due to this, the Imaging Business has been classified as a discontinued operation from the second quarter under review. As a result, a portion of the Condensed Consolidated Statements of Profit or Loss, Condensed Consolidated Statements of Cash Flows and Significant Notes Thereto for the six months ended September 30, 2019 have been reclassified in line with the presentation style for the six months ended September 30, 2020.

# Highlights

## 1H and 2Q Consolidated Financial Results

- ✓ Revenue: YoY decline in revenue slowed in 2Q, despite continuing COVID-19 headwinds
- ✓ Operating Profit: Achieved operating margin of approx. 10% in 1H due to SG&A streamlining even in difficult business environment  
Improved significantly to approx.15% in 2Q

## Full-Year Performance Forecasts

- ✓ COVID-19 impact will continue to improve gradually by the end of the fiscal year, revenue are expected to decrease by approx. 8% and securing operating profit of approx. ¥60 billion
- ✓ Plans for expenses and investments assume that business activities will become more active along with the recovery trend. However, depending on changes in the situation, we will further strengthen cost control
- ✓ Year-end dividend is planned to be ¥10 from the viewpoint of stable shareholder return and continuity although loss will be posted due to expenses related to the divestiture of the Imaging Business

# 01

---

## **Consolidated Financial Results and Business Review for the 2Q of Fiscal 2021 (FY Ending March 31, 2021)**

# 2Q of Fiscal 2021 (1) Consolidated Financial Results

- 1 Revenue: Decreased in 1H but YoY decline slowed in 2Q (1Q: -19% → 2Q: -8% after FX adjustment)
- 2 Operating profit: 2Q profitability showed remarkable improvement, resulted in operating margin of approx. 10% in 1H and 15% in 2Q alone, driven by revenue recovery and SG&A streamlining


		1H (Apr. - Sep.)			Supplemental data		2Q (Jul. - Sep.)			
(Billions of yen)		FY2020	FY2021	YoY	After FX adjustment	After FX and COVID-19 adjustment	FY2020	FY2021	YoY	After FX adjustment
Continuing operation*	Revenue	368.4	<b>1</b> 316.5	-14%	-13%	-46.0 billion	196.6	179.9	-8%	<b>1</b> -8%
	Gross profit (% of revenue)	242.8 (65.9%)	196.0 (61.9%)	-19%	-17%	-	130.3 (66.3%)	110.7 (61.6%)	-15%	-13%
	Selling, general and administrative expenses (% of revenue)	185.0 (50.2%)	161.5 (51.0%)	-13%	-12%	-	89.4 (45.5%)	81.1 (45.1%)	-9%	-10%
	Other income and expenses	-2.0	-4.2	-	-	-	-1.6	-3.0	-	-
	Operating profit (% of revenue)	55.8 (15.2%)	<b>2</b> 30.3 (9.6%)	-46%	-38%	-13.0 billion	39.3 (20.0%)	<b>2</b> 26.6 (14.8%)	-32%	-25%
	Profit before tax (% of revenue)	53.5 (14.5%)	28.3 (9.0%)	-	-	-	38.0 (19.3%)	25.6 (14.3%)	-	-
	Profit from continuing operation (% of revenue)	41.0 (11.1%)	25.9 (8.2%)	-¥15.1 billion	-	-	30.5 (15.5%)	26.1 (14.4%)	-¥4.4 billion	-
	Profit from discontinued operation	-5.0	-48.6	-¥43.6 billion	-	-	-3.0	-46.0	-¥43.0 billion	-
Continuing operation	Profit (loss)	36.1	-22.7	-¥58.8 billion	-	-	27.4	-19.9	-¥47.4 billion	-
	Profit (loss) attributable to owners of parent	36.1	-22.7	-¥58.8 billion	-	-	27.4	-20.0	-¥47.4 billion	-
	EPS	¥27	-¥18	-	-	-	-	-	-	-

\* The figures from "Revenue" to Profit from continuing operation" represents continuing operation.

\*\*Our calculations on the impact are based on the assumption that we would have achieved the same level of performance as the previous year if it is not for COVID-19, excluding FX impact, other income and expenses, and a one-off item (costs associated with voluntary recall of endoscopic products)..


# Updates: January to September

Medical revenue recovered to the previous year's levels in September






# 2Q of Fiscal 2021 (2) Endoscopic Solutions Division (ESD)



■ Revenue ■ Operating Profit  
(Billions of yen)



## ✓ Revenue

- 1H: Revenue decreased YoY due to COVID-19
- 2Q: YoY decline in revenue slowed from 1Q due to growth in Europe (+2% after FX adjustment), driven by UK and Eastern Europe

## ✓ Operating profit

Despite recording ¥6 billion in COGS for the voluntary recall of endoscopic products, operating margin stood at approx. 24% after FX adjustment, supported by SG&A streamlining

### 1H (Apr. - Sep.)

(Billions of yen)	FY2020	FY2021	YoY	After FX adjustment
Revenue	206.8	182.0	-12%	-10%
Operating profit	59.8	42.1	-30%	-25%
Other income / expenses	-0.3	-0.5	-	-
Operating margin	28.9%	23.1%		24.3%

### 2Q (Jul. - Sep.)

(Billions of yen)	FY2020	FY2021	YoY	After FX adjustment
Revenue	111.4	102.8	-8%	-7%
Operating profit	37.9	27.4	-28%	-23%
Other income / expenses	-0.4	-0.2	-	-
Operating margin	34.0%	26.7%		28.2%

### Reference


	FY2021 1Q	FY2021 2Q
YoY Revenue Comparison	-17%	-8%
After FX adjustment	-14%	-7%
Operating margin	18.5%	26.7%



# 2Q of Fiscal 2021 (3) Therapeutic Solutions Division (TSD)



■ Revenue ■ Operating Profit  
(Billions of yen)



## Revenue

- 1H: Revenue decreased YoY due to COVID-19
- 2Q: Recovering from 1Q to 2Q (1Q: -24% → 2Q: -6% after FX adjustment ) with the number of procedures coming back



## Operating profit

Operating margin exceeded 12% after FX adjustment in 1H as a result of improved revenue and continued cost control. 2Q operating margin exceeded the previous year's level

(Billions of yen)	1H (Apr. - Sep.)				2Q (Jul. - Sep.)			
	FY2020	FY2021	YoY	After FX adjustment	FY2020	FY2021	YoY	After FX adjustment
Revenue	108.0	90.9	-16%	-15%	56.0	52.8	-6%	-6%
Operating profit	15.2	10.2	-33%	-26%	9.5	8.8	-8%	0%
Other income / expenses	-0.7	-0.4	-	-	-0.6	-0.1	-	-
Operating margin	14.1%	11.2%		12.3%	17.1%	16.6%		18.0%

Reference		FY2021 1Q	FY2021 2Q
YoY Revenue Comparison		-27%	-6%
After FX adjustment		-24%	-6%
Operating margin		3.8.%	16.6%

# 2Q of Fiscal 2021 (4) Scientific Solutions Division (SSD)



■ Revenue ■ Operating Profit  
(Billions of yen)




## Revenue

1H: China grew as electric components and semiconductor industries are booming there, but revenue decreased YoY due to COVID-19



## Operating profit

Declined revenue led to lower profitability, but operating margin improved to 10% after FX adjustment in 2Q



### 1H (Apr. - Sep.)

(Billions of yen)	FY2020	FY2021	YoY	After FX adjustment
Revenue	49.7	40.3	-19%	-17%
Operating profit	5.4	0.2	-96%	-83%
Other income / expenses	-0.2	0	-	-
Operating margin	10.8%	0.6%		2.2%

### 2Q (Jul. - Sep.)

(Billions of yen)	FY2020	FY2021	YoY	After FX adjustment
Revenue	27.1	22.6	-17%	-17%
Operating profit	3.7	1.8	-51%	-39%
Other income / expenses	-0.1	0.3	-	-
Operating margin	13.8%	8.1%		10.0%

### Reference

	FY2021 1Q	FY2021 2Q
YoY Revenue Comparison	-21%	-17%
After FX adjustment	-18%	-17%
Operating margin	-	8.1%

# Statement of Financial Position

- ✓ Stated line items for discontinued operations' assets held for sale and liabilities directly associated with assets held for sale
- ✓ Secured on-hand liquidity for stable business operations in light of the impact of COVID-19

(Billions of yen)	End of Mar. 2020	End of Sep. 2020	Change		End of Mar. 2020	End of Sep. 2020	Change
Current assets	506.7	571.2	+64.5	Current liabilities	333.8	303.6	-30.2
Inventories	167.6	160.9	-6.7	Bonds/loans payable	81.0	49.2	-31.8
Assets held for sale	6.3	32.6	+26.4	Liabilities directly associated with assets held for sale	4.2	29.0	+24.8
Non-current assets	509.0	502.4	-6.6	Non current liabilities	309.9	442.3	+132.4
Property, plant and equipment	202.1	199.8	-2.3	Bonds/loans payable	199.9	333.5	+133.6
Intangible assets and others	208.5	203.9	-4.6	Equity	372.0	327.6	-44.4
Goodwill	98.3	98.7	+0.4	(Equity ratio)	36.5%	30.4%	-6.1pt
<b>Total assets</b>	<b>1,015.7</b>	<b>1,073.5</b>	<b>+57.9</b>	<b>Total liabilities and equity</b>	<b>1,015.7</b>	<b>1,073.5</b>	<b>+57.9</b>

**Interest-bearing debt: ¥382.7 billion (up ¥101.8 billion from March 31, 2020)**

# Consolidated Cash Flows

- ✓ Considering time deposits of ¥40 billion, FCF is plus ¥7.2 billion
- ✓ Financial CF: Plus ¥81.2 billion due to increase in long-term borrowings and issuance of corporate bonds

		1H (Apr. - Sep.)		
(Billions of yen)		FY2020	FY2021	Change
Continuing operation	Revenue	368.4	316.5	-51.9
	Operating profit	55.8	30.3	-25.5
	(% of revenue)	15.2%	9.6%	-5.6pt
	CF from operating activities	67.3	37.4	-29.9
	CF from investing activities	-31.4	-70.2	-38.8
	Free cash flow	35.9	-32.8	-68.7
	CF from financing activities	-10.5	81.2	+91.8
Discontinued operation	Cash and cash equivalents at end of period	135.5	210.5	+75.0

\* Please refer to Appendix (P.26) for cash flow of discontinued operation.

02

---

## **Forecasts for Fiscal 2021**

# Fiscal 2021 Consolidated Forecasts

- 1** Revenue : COVID-19 impact will continue to improve gradually by the end of the fiscal year, and revenue are expected to decrease by approx.8%
- 2** Operating Profit : Securing operating profit of approx. ¥60 billion by continuing to control SG&A expenses

(Billions of yen)		FY2020 (Results)**	FY2021 (Forecasts)	Change	YoY	After FX adjustment
Continuing operation *	Revenue	755.2	<b>1</b> 697.0	-58.2	-8%	-7%
	Gross profit	482.8	437.0	-45.8	-9%	-8%
	(% of revenue)	(63.9%)	(62.7%)			
	Selling, general and administrative expenses	381.2	366.0	-15.1	-4%	-3%
	(% of revenue)	(50.5%)	(52.5%)			
	Other income and expenses	-9.4	-10.5	-	-	-
	Operating profit	92.2	<b>2</b> 60.5	-31.7	-34%	-31%
	(% of revenue)	(12.2%)	(8.7%)			
	Profit before tax	86.6	58.5			
	(% of revenue)	(11.5%)	(8.4%)			
	Profit from continuing operation	60.6	47.5			
		(8.0%)	(6.8%)			
	Profit from discontinued operation	-8.9	-53.0			
	Profit (loss)	51.7	-5.5			
	Profit (loss) attributable to owners of parent	51.7	-5.5			
	(% of revenue)	(6.5%)	(-)			
	EPS	¥39	-¥4			

Dividend forecast in fiscal 2021

Year-end dividend of ¥10 per share

# Fiscal 2021 Forecasts by Business Segment

- 1** ESD・TSD : The number of procedures is on a recovery trend and although revenues are expected to decrease by approx. 7%, the operating margin in ESD will be approx.22% and in TSD will be approx. 11%
- 2** SSD : Business activities are expected to gradually recover from the second half of the fiscal year, but profits will decline for the full year due to lower revenue by COVID-19
- 3** Elimination and Corporate : Expect investments for strengthening IT infrastructure and QA/RA functions

(Billions of yen)		FY2020 (Results)*	FY2021 (Forecasts)	Change	YoY	After FX adjustment
ESD	Revenue	425.7	<b>1</b> 395.0	-30.7	-7%	-6%
	Operating profit	109.4	88.0	-21.5	-20%	-18%
TSD	Revenue	216.1	<b>1</b> 202.0	-14.1	-7%	-6%
	Operating profit	26.2	23.0	-3.2	-12%	-12%
SSD	Revenue	105.2	<b>2</b> 93.0	-12.2	-12%	-11%
	Operating profit	10.0	3.5	-6.5	-65%	-60%
Others	Revenue	8.2	7.0	-1.2	-15%	-15%
	Operating profit	-2.9	-3.0	-0.1	-¥0.1 billion	-¥0.1 billion
Elimination and Corporate	Operating profit	-50.5	<b>3</b> -51.0	-0.4	-¥0.4 billion	-¥0.5 billion
Consolidated Total	Revenue	755.2	697.0	-58.2	-8%	-7%
	Operating profit	92.2	60.5	-31.7	-34%	-31%
Discontinued operation	Revenue	42.2	20.0	-22.2	-53%	-53%
	Operating profit	-8.7	-53.0	-44.3	-¥44.3 billion	-¥44.5 billion



# 03

---

## **Transforming into a Truly Global Medtech Company**

# Committed to Corporate Reforms

## FY2021

Great chance to accelerate transformation to a truly global medtech company for sustainable growth



Focus the corporate portfolio



Structural reform of fixed costs



Successful launch of next-gen GI endoscopy system EVIS X1



Continued steady investment in product development for future growth



Driving efficiency in our R&D operations




### ☑ Continue ongoing reforms in 2H following our achievements in 1H

- Olympus and Japan Industrial Partners signed the definitive agreement to transfer our Imaging Business
- EVIS X1 has been launched in EMEA, some parts of Asia, and Japan
- “ENDO-AID”, a CAD platform for our endoscopy system, has been launched in EMEA and some parts of Asia in early November.
- Acquired FH ORTHO which develops and manufactures orthopedic devices and instruments
- Started deliberation on reorganization of domestic sales functions in the Olympus Group to strengthen sales capabilities

# AI-Powered CAD for Our Next-Gen Endoscopy System EVIS X1


ENDO-AID enables us to provide innovative technologies in each stage from detection to treatment  
Endoscopy system that sets new standards for endoscopic diagnosis and treatment



ENDO-AID, a CAD platform powered by AI that includes endoscopy application for the colon, has been launched in EMEA and some parts of Asia in early November.



White Light



ENDO-AID CADe  
with marker

The platform enables real-time display of automatically detected suspicious lesions and works in combination with EVIS X1.

It is expected to further strengthen our leadership in the GI endoscopy system with over 70% market share.

# Initiatives in Medical Field for Sustainable Growth



## Acquired FH ORTHO which develops and manufactures orthopedic devices and instruments

- The acquisition enables us to expand our orthopedic products that have been developed through Olympus Terumo Biomaterials Corp.\* and to expand the business via FH ORTHO's existing global distribution channels.
- We have also developed the first ultrasound device indicated for arthroscopic surgery. These underscore our commitment to expanding in the growing field of orthopedic minimally invasive surgery (MIS).




## Started deliberation on reorganization of domestic sales functions in the Olympus Group to strengthen sales capabilities

- Plan to integrate the domestic sales functions of both Olympus Corp. and Olympus Medical Science Sales Corp. for Medical and Scientific Solutions Businesses.
- Aim to realize flexible resource assignment, enhance cooperation with business partners, implement unified sales policy across Japan, and retain highly capable talent

\* Olympus is already active in orthopedics in Japan, where its joint venture Olympus Terumo Biomaterials Corp. distributes products such as bone substitutes and high tibial osteotomy (HTO) plates and screws.

# Key Product Catalysts: Endoscopic Solutions Division (As of Nov.13, 2020)



## Corporate Strategy of ESD : Further strengthen leadership in endoscopy



**Maintain leadership in conventional endoscopy** through continued innovation and commercial excellence



**Complement our portfolio with single-use endoscopes** to provide a comprehensive set of product offerings

Growth driver now	Just launched / Coming soon	Beyond
<p><b>GI endoscopy</b></p> <ul style="list-style-type: none"><li>▪ EVIS LUCERA ELITE (Japan, China)</li><li>▪ EVIS EXERA III (US, EU)</li></ul> <p><b>Surgical endoscopy</b></p> <ul style="list-style-type: none"><li>▪ VISERA ELITE II (US, EU, Japan)</li><li>▪ VISERA ELITE (China)</li><li>▪ VISERA 4K UHD (US, EU, Japan, China)</li></ul>	<p><b>GI endoscopy</b></p> <ul style="list-style-type: none"><li>▪ EVIS X1 (EU, Japan)</li><li>▪ TJF-Q190V, duodenoscope (US)</li><li>▪ ENDO-AID, endoscopy CAD platform for EVIS X1(EU)</li></ul>	<p><b>GI endoscopy</b></p> <ul style="list-style-type: none"><li>▪ EVIS X1(US, China)</li><li>▪ 3D function for EVIS X1</li><li>▪ Single-use duodenoscope</li></ul> <p><b>Surgical endoscopy</b></p> <ul style="list-style-type: none"><li>▪ VISERA ELITE II (China)</li><li>▪ New generation surgical endoscopy system(EU, Japan)</li></ul>

# Key Product Catalysts: Therapeutic Solutions Division (As of Nov. 13, 2020)



## Corporate Strategy of TSD : Focus and scale our TSD business



### GI endotherapy

Expand and accelerate portfolio in existing product categories and explore growth opportunities in adjacent areas



### Urology

Establish leadership in BPH and enhance position in stone management through portfolio expansion



### Respiratory endotherapy

Strengthen leadership by capturing the BLVR\* market and expand opportunities in early diagnosis and treatment of lung cancer

## Growth driver now

### GI endotherapy

- Visiglide series
- ESD Knife
- EZ Clip / QuickClip Pro
- EndoJaw

### Urology

- Resection electrode

### Respiratory endotherapy

- ViziShot series

## Just launched / Coming soon

### GI endotherapy

- 5 products (US)
- 5 products (EU)
- 10 products (Japan)
- 5 products (China)

### Urology

- iTind, non-surgical device for Benign Prostatic Hyperplasia (US, EU)
- SOLTIVE SuperPulsed Laser System\*\*, stone lithotripsy system (US, EU)

## Beyond

### GI endotherapy

- Single-use cholangioscope

### Urology

- Single-use ureteroscope

### Respiratory endotherapy

- Single-use bronchoscope

\* Bronchoscopic Lung Volume Reduction \*\* Please refer to Appendix (P.28) for the detail of SOLTIVE SuperPulsed Laser System.

**OLYMPUS**

A thick, yellow, horizontal swoosh underline that is slightly wider in the center, positioned directly beneath the word OLYMPUS.




# 04

---

## Appendix

# Supplementary Materials: 2Q of Fiscal 2021 Factors that Affected Consolidated Operating Profit




# Supplementary Materials: 2Q of Fiscal 2021 Results by Segment

		1H (Apr. - Sep.)				2Q (Jul. – Sep.)			
(Billions of yen)		FY2020	FY2021	YoY	After FX adjustment	FY2020	FY2021	YoY	After FX adjustment
ESD	Revenue	206.8	182.0	-12%	-10%	111.4	102.8	-8%	-7%
	Operating profit	59.8	42.1	-30%	-25%	37.9	27.4	-28%	-23%
TSD	Revenue	108.0	90.9	-16%	-15%	56.0	52.8	-6%	-6%
	Operating profit	15.2	10.2	-33%	-26%	9.5	8.8	-8%	0%
SSD	Revenue	49.7	40.3	-19%	-17%	27.1	22.6	-17%	-17%
	Operating profit	5.4	0.2	-96%	-83%	3.7	1.8	-51%	-39%
Others	Revenue	3.8	3.2	-16%	-16%	2.1	1.6	-21%	-21%
	Operating profit	-1.3	-1.0	+¥0.4 billion	+¥0.4 billion	-0.7	-0.4	+¥0.2 billion	+¥0.2 billion
Elimination and Corporate	Operating profit	-23.3	-21.2	+¥2.0 billion	+¥1.9 billion	-11.3	-11.0	+¥0.3 billion	+¥0.3 billion
Consolidated Total	Revenue	368.4	316.5	-14%	-13%	196.6	179.9	-8%	-8%
	Operating profit	55.8	30.3	-46%	-37%	39.3	26.6	-32%	-25%
Discontinued operation	Revenue	20.8	13.7	-34%	-33%	10.8	8.0	-26%	-26%
	Operating profit	-4.9	-48.5	-¥43.6 billion	-¥43.8 billion	-3.1	-46.0	-¥42.9 billion	-¥43.0 billion

# 2Q of Fiscal 2021 Discontinued Operation (IMD)



■ Revenue ■ Operating Profit (Loss)  
(Billions of yen)



**Revenue**

1H: Revenue significantly declined due to COVID-19



**Operating profit**

Operating loss was posted due mainly to expenses related to the divestiture of the Imaging business (43.7 billion yen)

1H (Apr. - Sep.)

(Billions of yen)	FY2020	FY2021	YoY	After FX adjustment
Revenue	20.8	13.7	-34%	-33%
Operating profit	-4.9	-48.5	-¥43.6 billion	-¥43.8 billion
Other income / expenses	-1.0	-43.9	-	-
Operating margin	-	-	-	-

2Q (Jul. - Sep.)

(Billions of yen)	FY2020	FY2021	YoY	After FX adjustment
Revenue	10.8	8.0	-26%	-26%
Operating profit	-3.1	-46.0	-¥42.9 billion	-¥43.0 billion
Other income / expenses	-0.5	-43.6	-	-
Operating margin	-	-	-	-

## Reference

	FY2021 1Q	FY2021 2Q
YoY Revenue Comparison	-41%	-26%
After FX adjustment	-39%	-26%
Operating margin	-	-

## Cash flow of discontinued operation


	1H (Apr. - Sep.)		
	FY2020	FY2021	Change
CF from operating activities	-1.3	-2.2	-0.9
CF from investing activities	-1.5	-0.5	+0.9
CF from financing activities	-0	-0.1	-0

# Supplementary Materials: Expenditures etc.

## 1H Results and Full-year Forecasts

(Billions of yen)

■ FY2020 1H ■ FY2021 1H ■ FY2021 (Forecast)



(Billions of yen)

FY2020 1H

FY2021 1H

R&D expenditures\* (a)

42.6

39.0

Capitalization of R&D expenditures (b)

8.4

7.4

R&D expenses in P/L (a-b)

34.2

31.6

(Billions of yen)

FY2020 1H

FY2021 1H

Amortization

3.3

3.9

End of Jun, 2020

End of Sep, 2020

R&D assets

49.2

51.3

\* Capitalization of R&D expenditures (b) are included in R&D expenditures.

\*\* Capitalization of R&D expenditures (b) are included in capital expenditures.


In addition, the Olympus Group has adopted IFRS 16 "Leases" from the fiscal year 2020, and right-of-use assets below are included in capital expenditures.

(FY2020 1H: ¥5.2 billion, FY2021 1H: ¥8.4 billion, FY2021 Forecast: ¥34.0 billion)

# Supplementary Materials: New Products in Urology



## iTind



Product summary:

- iTind is a non-surgical device for the minimally invasive treatment of Benign Prostatic Hyperplasia (BPH).
- This novel device strengthens the already robust Olympus urology portfolio by offering expanded options in enhanced patient care.

Launch area:

- US, EU

## SOLTIVE SuperPulsed Laser System



SOLTIVE Premium SuperPulsed Laser System (right)  
SOLTIVE Pro SuperPulsed Laser System (left)

Product summary:

- The SOLTIVE SuperPulsed Laser System is a new application of thulium fiber laser technology designed for stone lithotripsy and soft tissue applications.
- Efficient stone dusting contributes to shortening surgery time and decreasing the burden on patients.

Launch area:

- US, EU